Complementary Testing to Further Evaluate the Immunogenicity of a GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Aged Over 26 Years Enrolled in Study 104820.
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2016
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 21 Feb 2008 Status changed from in progress to completed, according to ClinicalTrial.gov
- 29 May 2007 Status changed from recruiting to in progress.
- 17 Apr 2007 New trial record.